Last reviewed · How we verify
Test formulation D2
At a glance
| Generic name | Test formulation D2 |
|---|---|
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Study of FZ008-145 in Healthy Subjects. (PHASE1)
- A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age (PHASE1, PHASE2)
- ONC201 in Pediatric H3 K27M Gliomas (PHASE1)
- A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body (PHASE1)
- Pharmacokinetics Of Celecoxib Test Formulations (PHASE1)
- Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years (PHASE2)
- Relative Bioavailability Trial of Oral Dispersible Praziquantel Tablets in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Test formulation D2 CI brief — competitive landscape report
- Test formulation D2 updates RSS · CI watch RSS
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. portfolio CI